Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ...
Nuance Pharma completes patient recruitment for ENHANCE-CHINA phase 3 trial of ensifentrine (Ohtuvayre™) for COPD treatment in China, following US FDA approval in 2024. The trial, led by Professor Zhong Nanshan, aims to evaluate efficacy and safety over 24 weeks in 46 hospitals.
Related Clinical Trials
Highlighted Terms
Related News
Nuance Pharma completes recruitment for ENHANCE-CHINA, the phase 3 clinical trial of ...
Nuance Pharma completes patient recruitment for ENHANCE-CHINA phase 3 trial of ensifentrine (Ohtuvayre™) for COPD treatment in China, following US FDA approval in 2024. The trial, led by Professor Zhong Nanshan, aims to evaluate efficacy and safety over 24 weeks in 46 hospitals.